Long-term use of rituximab increases T cell count in MS patients

Overview of attention for article published in Frontiers in immunology, July 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

So far, Altmetric has seen 1 blog post.

CD20-depletion with rituximab which is currently not approved for MS, but is widely used in rituxiland rather than spending…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.